High Free Cash Flow Stocks
ANIP is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
ANI PHARMACEUTICALS INC (ANIP) Stock Price & Overview
NASDAQ:ANIP • US00182C1036
Current stock price
74.21 USD
-1.75 (-2.3%)
At close:
74.21 USD
0 (0%)
After Hours:
The current stock price of ANIP is 74.21 USD. Today ANIP is down by -2.3%. In the past month the price decreased by -1.84%. In the past year, price increased by 9.91%.
ANIP Key Statistics
52-Week Range56.71 - 99.5
Current ANIP stock price positioned within its 52-week range.
1-Month Range70.15 - 78.1
Current ANIP stock price positioned within its 1-month range.
- Market Cap
- 1.664B
- P/E
- 9.43
- Fwd P/E
- 8.16
- EPS (TTM)
- 7.87
- Dividend Yield
- N/A
ANIP Stock Performance
Today
-2.3%
1 Week
+0.09%
1 Month
-1.84%
3 Months
-5.38%
Longer-term
6 Months -17.21%
1 Year +9.91%
2 Years +12.44%
3 Years +96.74%
5 Years +122.99%
10 Years +63.21%
ANIP Stock Chart
ANIP Stock Screens
ANIP currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
ANIP is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
ANIP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ANIP. When comparing the yearly performance of all stocks, ANIP turns out to be only a medium performer in the overall market: it outperformed 44.2% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ANIP Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ANIP. While ANIP belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ANIP Earnings
On February 27, 2026 ANIP reported an EPS of 2.33 and a revenue of 247.06M. The company beat EPS expectations (14.48% surprise) and beat revenue expectations (4.62% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 27, 2026
PeriodQ4 / 2025
EPS Reported$2.33
Revenue Reported247.06M
EPS Surprise 14.48%
Revenue Surprise 4.62%
ANIP Forecast & Estimates
14 analysts have analysed ANIP and the average price target is 112.2 USD. This implies a price increase of 51.19% is expected in the next year compared to the current price of 74.21.
For the next year, analysts expect an EPS growth of 15.55% and a revenue growth 20.75% for ANIP
Analysts
Analysts84.29
Price Target112.2 (51.19%)
EPS Next Y15.55%
Revenue Next Year20.75%
ANIP Groups
Sector & Classification
ANIP Financial Highlights
Over the last trailing twelve months ANIP reported a non-GAAP Earnings per Share(EPS) of 7.87. The EPS increased by 51.35% compared to the year before.
Income Statements
Revenue(TTM)883.37M
Net Income(TTM)70.21M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.95% | ||
| ROA | 4.87% | ||
| ROE | 12.98% | ||
| Debt/Equity | 1.11 |
Chartmill High Growth Momentum
EPS Q2Q%42.94%
Sales Q2Q%29.64%
EPS 1Y (TTM)51.35%
Revenue 1Y (TTM)17.5%
ANIP Ownership
Ownership
Inst Owners96.24%
Shares22.42M
Float19.13M
Ins Owners6.27%
Short Float %18.84%
Short Ratio9.42
ANIP Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANIP
Company Profile
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Company Info
IPO: 2000-05-04
ANI PHARMACEUTICALS INC
210 Main Street West
Baudette MINNESOTA 56623 US
CEO: Nikhil Lalwani
Employees: 970
Phone: 13026587581
ANI PHARMACEUTICALS INC / ANIP FAQ
What does ANIP do?
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Can you provide the latest stock price for ANI PHARMACEUTICALS INC?
The current stock price of ANIP is 74.21 USD. The price decreased by -2.3% in the last trading session.
Does ANIP stock pay dividends?
ANIP does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANIP stock?
ANIP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of ANI PHARMACEUTICALS INC (ANIP) based on its PE ratio?
The PE ratio for ANI PHARMACEUTICALS INC (ANIP) is 9.43. This is based on the reported non-GAAP earnings per share of 7.87 and the current share price of 74.21 USD.
What is the ownership structure of ANI PHARMACEUTICALS INC (ANIP)?
You can find the ownership structure of ANI PHARMACEUTICALS INC (ANIP) on the Ownership tab.